Life Science Nation Collaborates with McDermott Will & Emery to Host the Inaugural RESI Asia Conference

19 Sep

By Gregory Mannix, Vice President International Business Development, LSN

The Creation of a Global Fundraising Superstructure

Life Science Nation (LSN) is collaborating with McDermott Will & Emery (McDermott) to bring the Redefining Early Stage Investments (RESI) Conference to Asia for the first time. McDermott is a co-sponsor of RESI Asia and will be hosting the global law firm’s 3rd Annual Shanghai Life Sciences Symposium during the RESI Shanghai Event.  The McDermott Symposium will cover hot legal topics in the life sciences and health industries, including international investment, regulatory frameworks in the US and Europe, IP and data protection and “Key Legal Issues on Cross-Border M&A Transactions”. McDermott will invite industry leaders and the program will feature more than a dozen leading attorneys who specialize in the life sciences and healthcare from the US, Europe and China.

RESI Asia will be comprised of RESI Shanghai, taking place on November 12th at the Ritz-Carlton Pudong, and RESI Taipei, taking place on November 14th at the Taipei International Convention Center. These new events, combined with RESI San Francisco, RESI Europe, RESI Philadelphia and RESI Boston in 2019, create a global superstructure for funding early stage assets across the silos of drugs, devices, diagnostics and digital health. This allows fundraising CEOs, investors and channel partners to meet every few months and form global relationships with partners who fit their strategic interests.

Dennis Ford, CEO of LSN and creator of the RESI Conference Series, said that “McDermott has been a longtime partner with LSN.  McDermott was one of our biggest supporters when we launched RESI 6 years ago. Over the years, the partnership has grown to be very complementary to the LSN & McDermott early-stage life science strategies. Together, we have expanded our businesses across the U.S., Europe and now Asia.”

“We are pleased to work with our longtime partners at LSN on our third annual Shanghai Life Sciences Symposium, to be held this year as part of the first-ever RESI Shanghai,” said Michelle Gon, a McDermott Partner stationed in Shanghai .  “This collaboration will provide life sciences companies and funds in China, Europe and the US with the strategies and connections that they need to attract investment resources and grow.  We look forward to this jointly organized event on November 12th in Shanghai, and to co-sponsoring RESI Taipei two days later on November 14th.”

The Asia region has become more central to life science innovation and investment over the last several years. LSN plans to bring fundraising CEOs and investors from outside of Asia who have an interest in accessing the vast Asian marketplace, whether to take advantage of clinical trials or get new products into the key Asian markets. Taipei is a technology leader in nanotechnology, robotics and custom silicon chip monitoring and control devices that will change the fabric of the healthcare world. LSN aims to open up the Asia Pacific to our North American and European constituents fostering partnerships and investment syndicates resulting in new global alliances.

About Life Science Nation

Life Science Nation (LSN) is a global partnering ecosystem that allows early-stage companies with compelling technology assets to get plugged into the early-stage investor and channel partner’s radars with minimal cost and a big ROI. LSN is a global matching platform for early-stage buyers and sellers across the domains of Drugs, Devices, Diagnostics and Digital Health – the “4 Ds”. LSN curates two databases: a buy-side of global cross-border early-stage investors/partners and a sell-side of global cross-domain technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel, pipeline and portfolio development. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, a funding superstructure that runs five times a year during J.P. Morgan in San Francisco (January), alongside BIO Europe (March), alongside BIO U.S (June), Boston (September) and Asia in Shanghai and Taipei (November). LSN also owns and operates the Focus on Cures Accelerator (FOC) that provides international startups a Boston-based footprint and helps them develop and execute a global investor and channel partner strategy. Learn more at

About McDermott Will & Emery

McDermott’s global Life Sciences team fuels the mission of life sciences companies, leveraging a purpose-built and dedicated group of lawyers with demonstrated strengths across intellectual property, regulatory, transactional, employment and litigation law. Combining industry leadership and passion for the work they do – and leveraging the Firm’s deep health care experience – team members are routinely listed as “Life Sciences Stars” by LMG Life Sciences. Additionally, the Firm’s Life Sciences Intellectual Property team was ranked as a leading US practice in Life Sciences on Managing IP’s “2018 IP Stars” list.  Learn more at

For more information

Contact: the RESI Team at, or McDermott at

Regional Early Stage Players Need to Go Global

19 Sep

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

It took time and determination to create a global early stage funding and partnering ecosystem. With the advent of Life Science Nation’s (LSN) two up and coming RESI Asia events. LSN now has a truly unique funding and partnering infrastructure that can be utilized to bring regional technology assets catapulting into the global partnering and commercial distribution arena.

The life science market is an interwoven global fabric – countries in both hemispheres have been collaborating for decades; whether it be academia, foundations or governmental initiatives. Partnering takes the form of cross-border research collaboration, product development, investment and distribution.

Everything starts with international R&D, with advancement fueled by international links and partnerships that have been forged for decades to drive the science and help save lives. Government agencies in The U.S. and Europe have been working with Asian counterparts for years to form agreements on standardized testing and development mechanisms globally.

This standardization is critical so that drug, device and diagnostic product developers can choose from an array of global service providers offering better, faster, cheaper vehicles to validate and certify their products for global commercialization. A global one-stop-shop model for development services can dramatically impact the time factor holding the industry hostage for years.

There will be a tsunami of next generation healthcare products that will dramatically impact the world in the coming decade.  The new science impacting next generation healthcare product development is well documented. Getting these new products validated and certified will require a global vision that takes advantage of service providers regardless of their geographic location.

Back to LSN and the RESI global ecosystem… scientist-entrepreneurs and fundraising CEOs can hop into the RESI partnering ecosystem and develop the investor, service provider and distribution channel partners that will get them to the market faster and cheaper.

The interwoven global fabric of the life science community has taken decades to develop: LSN, with our RESI partnering conferences, hopes to make is easier for the regional early stage players around the world to adroitly take advantage of the burgeoning global market.

Get Your Name Out – Win a Pitch Spot in the RESI Asia Innovation Challenge!

19 Sep

By Claire Jeong, Director of Research, Asia BD, LSN

claireAfter another successful RESI Boston last week, we are excited to talk about our inaugural RESI Asia events, RESI Shanghai (November 12th) and RESI Taipei (November 14th)!

Life Science Nation would like to invite all early-stage life science companies across the globe to apply for the RESI Asia Innovation Challenge through our online portal. Selected finalists will present a poster showcasing their company and technology at our exhibition hall on the day of RESI. All participants will be presented with “RESI Cash” to “invest” in their favorite technologies. This time, we have another special opportunity for the Innovation Challenge finalists!

For the very first time, our RESI Asia conferences will feature a full day track dedicated to pitch sessions, during which companies will present a short pitch in front of a panel of active investor judges. At both RESI Shanghai and RESI Taipei, companies who are selected for the Innovation Challenge will also be granted an opportunity to be part of a pitch session. In combination, the Innovation Challenge and pitch sessions will provide unparalleled exposure to participating early-stage companies who are seeking to meet and grow relationships with new and existing investors for their fundraising efforts.

To shed some light on what the Innovation Challenge is like from the participating company’s point of view, the 1st place winner of the Innovation Challenge at RESI Boston, Zepto Life Technology, shared some comments about their experience at RESI. Jason Payne, Director of Business Development & Investor Relations at Zepto, said, “The RESI Innovation Challenge provided a truly excellent opportunity for my team to showcase Zepto’s pioneering GMR-based “lab-on-a-chip” biotechnology, ahead of our firm’s upcoming $30 million Series A round in 1Q 2020. RESI’s team of well-practiced professionals equipped Zepto with expert guidance throughout each step of the process — from our team’s initial creation of Zepto’s poster through the entire RESI conference’s celebration of Zepto’s eventual 1st Place finish. Moreover, the RESI conference’s excellent web-based scheduling system allowed Zepto to launch our firm’s Series A outreach in style, introducing my team to numerous potential investors with a simple click of my mouse. Thanks to RESI, Zepto’s fundraising process is off to a wonderful start!”

Carmit Levy, CEO of ResMetrix Medical, 3rd place winner in the Innovation Challenge at RESI Boston, added, “The RESI Innovation Challenge provided a great opportunity for Resmetrix to present our unique wearable system for accurately monitoring lung disease patients at home and alert for early signs of deterioration. It opened the possibility to meet other participants that were interested to hear more about Resmetrix technology on top of the meetings that we set before with investors, through the wonderful meetup system on RESI website. Winning 3rd place in RESI challenge also exposed Resmetrix to additional potential investors. Thank you RESI for this great opportunity!”

I’ve also interviewed Soundable Health’s CEO Catherine Song, who won 1st place at the RESI Philadelphia Innovation Challenge in June (you can read it here).

Applying for the Innovation Challenge is free – get started on your application now!

RESI ASIA Innovation Challenge Deadline is Oct. 11th, 2019

%d bloggers like this: